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ABSTRACT
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of
the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC)
mediated by NK cells. NK cells acquire surface CD137 expression in the presence of solid-phase-attached
daratumumab and when encountering a daratumumab-coated CD38+ tumor cell line. In this setting,
addition of the agonist anti-CD137 mAb urelumab enhances NK-cell activation increasing CD25 expres-
sion and IFNɣ production. However, in vitro ADCC is not increased by the addition of urelumab both in
4h or 24h lasting experiments. To study urelumab-increased daratumumab-mediated ADCC activity
in vivo, we set up a mouse model based on the intravenous administration of a luciferase-transfected
multiple myeloma cell line of human origin, human NK cells and daratumumab to immuno-deficient
NSG mice. In this model, intravenous administration of urelumab 24h after daratumumab delayed tumor
growth and prolonged mice survival.
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CD38 is a transmembrane protein expressed on all malignant
plasma cells in multiple myeloma.1 The anti-CD38 IgG1
human monoclonal antibody daratumumab is used in combi-
nation with other drugs in relapsed or refractory multiple
myeloma patients2 and has been recently approved in combi-
nation with bortezomib, melphalan, and prednisone for newly
diagnosed multiple myeloma.3 Its clinical activity is contin-
gent on antibody dependent-cellular cytotoxicity (ADCC) as
mediated by NK cells and macrophages4,5 and probably the
additional poorly understood effects of CD38 ligation on
immune system cells and on myeloma cells themselves.6
Complement-mediated cytotoxicity and reductions of mye-
loid-derived suppressor cells in the myeloma microenviron-
ment have also been observed.4,7 CD137 (4-1BB) is a TNFR
family surface glycoprotein expressed on activated T and NK
cells.8 Agonist monoclonal antibodies directed to CD137, such
as urelumab, enhance T-cell mediated antitumor immunity9
and have been shown to enhance anti-tumor ADCC as
mediated by rituximab,10 cetuximab,11 and trastuzumab.12
The mechanism proposed is that CD16 (FcRɣIIIa) ligation
by a cell surface-bound IgG1 Fc leads to the induction of
CD137 on the surface of NK cells. Once on the NK surface,
if CD137 is stimulated by a CD137 agonist antibody, it
enhances the survival and cytotoxic performance of NK cells
in terms of more efficient ADCC.10–12 These preclinical stu-
dies support the combined use of daratumumab with urelu-
mab in multiple myeloma including evidence in NK-
humanized mice.
Results and discussion
We hypothesized that daratumumab could synergize with
urelumab and perhaps other CD137 agonists in its activity
against multiple myeloma. We first found that plastic-bound
daratumumab, as any other human IgG1 antibody, induces in
16 hours surface expression of CD137 on resting NK cells
freshly isolated from peripheral blood of healthy donors
(Figure 1(a)). Of note, such an activity was not further
increased by incubation with known NK-stimulating cyto-
kines such as IL-2, IL-15 or IL-12 (Figure 1(a)). Consistent
with this, if the CD38+ multiple myeloma-derived cell line
MM1S-GFP-Luc (Supp. Figure 1) was coated with daratumu-
mab but not with irrelevant human IgG, it induced CD137
surface expression on cocultured resting NK cells
(Figure 1(b)). This effect was not enhanced by the addition
of cytokines to the 16-hour cocultures. These results were
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recapitulated with the multiple myeloma cell line KMS28-BM
coated with daratumumab (Supp. Figure 2A). NK cells that
upregulated CD137 on the membrane were mostly CD56dim.
Moverover, NK cells positive for CD25, CD94, NKG2D and
NKG2A expressed more frequently CD137 on the membrane
than those NK cells that did not expressed these markers
(Figure 1(c)). However, CD16+ cells expressed less frequently
CD137 than CD16− NK cells, as had been previously
descrided.12 Importantly, gated NK cells in seven bone-
marrow aspirates from multiple myeloma patients upregu-
lated CD137 in short-term cultures when daratumumab was
added (Figure 1(d)). CD38 expression on normal and clonal
plasma cells as well and on other lymphoid and myeloid
populations of one of the patient bone marrow was studied,
confirming expression not only on plasma cells but also on
a variety of lymphoid and myeloid cells including NK cells
(Supp. Figure 3).
To ascertain if CD137 ligation by urelumab costimulated NK
cells, we exposed freshly isolated humanNK cells to plate-bound
human IgG1 in order to upregulate surface CD137 and har-
vested these cells 24h later to be exposed to MM1S-GFP-Luc
cells coated with daratumumab in the presence or absence of
Figure 1. CD137 expression on NK cells is induced by immobilized monoclonal antibodies. (a) CD137 expression on NK cells cultured during 16h in plates coated with
human IgG or daratumumab in the presence or absence of indicated cytokines. Bar graphs show data using NK cells from 4 unrelated subjects. Cultures were set up
in the presence of the indicated cytokines. (b) CD137 expression on NK cells cocultured during 16h with the multiple myeloma MM1S-GFP-Luc cell line with or
without daratumumab in the presence or absence of different cytokines. Bar graphs represent data from three independent experiments with NK cells from different
donors. (c) CD137 co-expression with CD56, CD16, CD25, CD94, NKG2D and NKG2A on NK cells cultured during 16h in plates coated with human IgG. Paired dots in
the graphs indicate data from each subject. (d) FACS-Gating strategy and CD137 expression on NK cells from bone marrow aspirates taken from multiple myeloma
patients, that were cultured during 16h with daratumumab or irrelevant human IgGs. A representative contour plot and a bar graph with data from 7 subjects are
shown. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 in a paired T-test or one-way ANOVA test.
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soluble urelumab that was added to these 24 and 48h cultures.
Figure 2(a) shows that urelumab increased the level of CD25
surface expression, as well as the intracellular content of IFNɣ
(Figure 2(c)). In these co-cultures, CD137 was co-expressed with
CD25 on NK cells (Figure 2(b)), and the fraction of NK cells
expressing a higher level of intracellular IFNɣ, co-expressed
more frequently CD137 (Figure 2(e)). Co-expression of other
NK cell markers was also studied in this setting (Supp. Figure
4A-F). NK cells that expressed more PD-L1, LAG-3, NKG2D,
CD94 and NKG2A on the membrane, expressed more fre-
quently CD137 than their negative counterparts. In the same
way, NK cells containing more Granzyme B exhibited a higher
proportion of CD137+ cells. Moreover, the supernatants of such
cultures showed higher concentrations of secreted IFNɣ in the
presence of urelumab (Figure 2(d)). These results were also seen
in independent series of coculture experiments with the KMS28-
Figure 2. Urelumab increases daratumumab-mediated NK cell activation. (a) Urelumab increases CD25 expression on NK cells cultured during 16h with IL-2 and
immobilized IgG and then cocultured 24h/48h with MM1S-GFP-Luc cells, daratumumab, and urelumab. (b) Percentage of CD137+ NK cells among the CD25+ and
CD25− cell fractions of the corresponding co-cultures of NK cells as in A. A representative FACS contour plot is shown. (c) Urelumab increases IFNɣ intracellular
expression in NK cells cultured as in A. (d) Urelumab increases IFNɣ release to the supernatant by NK cells cultured as in A. This graph shows data of one experiment
from three independently performed with similar results. (e) Percentage of CD137+ NK cells among the IFNɣ+ and IFNɣ− cell fractions of the corresponding co-
cultures of NK cells as in A. A representative FACS contour plot is shown. Cytometry results are representative of five different donors. * = p < 0.05, ** = p < 0.01 and
*** = p < 0.001 in a paired t-Test or one-way ANOVA test.
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BM cell line (Supp. Figure 2B-D) that also express daratumu-
mab-recognizable CD38 (Supp. Figure 1). The anti-SLAMF7
mAb elotuzumab, approved for multiple myeloma treatment13
showed similar effects upregulating CD137 expression upon co-
culture of NK cells with multiple myeloma cell lines expressing
SLAMF7 (Supp. Figure 5A-B) resulting in enhanced of CD25
expression and IFNɣ production when urelumab was added to
the cultures (Supp- Figure 5C-D).
We repeatedly tried to see if such CD137-stimulated NK
cells would perform better in ADCC assays.10–12 However, in
these types of cultures such an enhancement of the cytotoxicity
triggered by daratumumab could not be observed (Figure 3(a)).
In line with this, CD16 engagement by myeloma cell-coated
daratumumab resulted in downregulation of surface CD16
expression but again, this effect was not modified by urelumab
(Figure 3(b)). NK-cell degranulation was also studied in such
co-cultures, where only minor increases of CD107a surface
expression on NK cells could be observed under the influence
of urelumab (Figure 3(c)). Thinking that this negative result
was due to insufficient CD137 induction, we performed experi-
ments with NK cells that had been co-cultured for a week in
the presence of an irradiated lymphoblastoid cell line plus
recombinant IL-2, which showed high levels of CD137 expres-
sion and overall activation (Supp. Figure 6A). The purity of
isolated NK cells was verified in each case (Supp. Figure 7B).
ADCC mediated by activated and expanded NK cells was of far
greater intensity than that performed by freshly harvested NK
cells (Supp. Figure 7C). However, even when using these acti-
vated NK cells, the effect of adding urelumab to ADCC cyto-
toxicity cultures against daratumumab–coated MM1S-GFP-Luc
cells was again negligible (Supp. Figure 6B-C). Our data indi-
cate that at least in this myeloma model, enhancement of NK
mediated ADCC by urelumab is not mediating any prominent
effect, albeit CD137 ligation clearly augmented NK-cell produc-
tion of IFNɣ.
To model in vivo the effects of urelumab on NK antitumor
activity upon daratumumab treatment, we used a model of
NSG mice reconstituted with human NK cells. In this setting,
mice intravenously injected with luciferase-transfected
MM1S-GFP-Luc cells were given 2 × 106 human NK cells
and daratumumab i.v. on the same day. Twenty-four hours
later, mice were dosed with urelumab, once having given time
for CD137 induction. A purity check of the administered NK
cells is shown in supplementary figure 7A. Twenty four hours
after administration, MM1S-GFP-Luc and NK cells were
present in bone marrow. Human NK cells could also be
found in blood, liver and spleen of the mice (Supp. Figure. 8).
Comparing the different treatment groups by measuring
tumor-emitted bioluminescence and survival, it was clear that
the daratumumab and NK + daratumumab groups showed
disease control over the untreated group and the group
receiving NK cells. Importantly, the group given triple treat-
ment with NK transfer, daratumumab and urelumab had
significantly better tumor control (Figure 4(a-b)) and survival
advantage over the daratumumab + NK group (Figure 4(c)).
Similar experiments were carried out with the lymphoblastoid
cell line+IL-2 activated NK cells. In these experiments, the
group co-treated with urelumab again showed a certain
degree of survival advantage (Supp. Figure 9A). Of note,
daratumumab as a single agent without NK cell transfer
exerted some antitumor effects that could be related to
ADCC performed by murine macrophages, but this effect is
not enhanced by urelumab in ausence of human NK cells
(Supp. Figure 9B).
Considering these results as a whole, we conclude that even
in the absence of effects on CD8 T cells,14 addition of urelu-
mab to daratumumab treatment may improve therapeutic
outcomes. Given the fact that urelumab at full doses causes
liver inflammation in a subset of patients,15 testing other safer
or targeted CD137 agonists in the same setting will be impor-
tant. It is surprising that the pharmacological interaction
mechanism between daratumumab and urelumab seems not
to be a mere enhancement of the effector phase of ADCC as
proposed by H. Kohrt et al.10–12 but probably involves
a higher level of intricacy. This could involve the immunor-
egulatory and proinflammatory functions of NK cells. We
cannot exclude agonist effects of CD38 ligation on NK cells
themselves that could potentially further foster their
activation.16 Indeed, we confirmed the binding of daratumu-
mab to a large fraction of NK cells (data not shown).
Furthermore, in immunocompetent patients, anti-CD137
and anti-CD38 mAb may act on their target molecules on
T lymphocytes thereby potentially enhancing and consolidat-
ing therapeutic efficacy through amplification of adaptive
immunity. In this regard, we have previously reported
enhancement of CD8+ T-cell immunity by agonist anti-CD
137 mAbs against syngeneic myeloma mouse models.17 Our
model system in NSG mice permits us to focus on NK-
mediated mechanisms since complement activation and
macrophage functions are deficient in this mouse model.
Figure 3. Urelumab does not increase daratumumab-mediated ADCC in culture (a) Urelumab does not increase direct ADCC effects exerted by NK cells cultured as in
Figure 2(a), that was measured as the % of MM1S-GFP-Luc dead cells at 1:1 E:T ratio. (b) Percentage of NK cells expressing CD16 when cultured as in Figure 2(a). (a
and b) include results from seven different donors. (c) Surface CD107a expression on NK cells cultured as in Figure 2(a) corresponding to five different healthy donors.
* = p < 0.05, ** = p < 0.01 and *** = p < 0.001 in a paired t-Test or one-way ANOVA test.
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Additionally, urelumab decreases antibody responses through
a route dependent on T follicular helper cells.18 This may help
reduce anti-drug antibodies.
Clinical trials are ongoing testing the combination of low-
dose urelumab with elotuzumab, another anti-myeloma
ADCC-inducing antibody (NTC02252263). Effects of the dar-
atumumab + urelumab combination in a xenografted multiple
myeloma model advocate for a clinical trial to sustain and
enhance with CD137 agonists the outstanding effects pro-
duced by daratumumab against myeloma.
Material and methods
Tumor cell lines
MM1S-GFP-Luc19,20 and KMS28-BM21 cell lines were kindly
provided by Dr. Maiso and Dr. Agirre (CIMA, Universidad de
Navarra). RPMI8866 were gifted by Dr. Lopez-Botet (IMIM,
Barcelona). Cell lines were maintained at 37°C in 5% CO2 and
were grown in RPMI medium (RPMI 1640) with Glutamax
(Gibco, Invitrogen) containing 10% heat-inactivated FBS
(Gibco, Invitrogen), 100 IU/mL penicillin and 100 g/mL
streptomycin (Biowhittaker). MM1S-GFP-Luc cells were also
cultured in the presence of 500µg/mL of G418 (Sigma-
Aldrich).
Isolation and activation of NK cells
Blood samples were obtained from healthy volunteers through
the Banco de Sangre y Tejidos de Navarra while the fulfilling
the requirements of the Clinical Research Ethics Committee
of the Navarre Government following the 2016.143 protocol.
PBMCs from buffy coats were isolated after gradient centri-
fugation with Ficoll-Paque (GE Healthcare), and NK cells
were isolated by negative selection using magnetic beads and
LS selection columns following the manufacturer’s protocol
(Miltenyi Biotec).
When indicated, NK cells were cultured during 16h in
plastic culture plates coated by daratumumab or irrelevant
human IgG. For this, a solution of antibody (10µg/mL) in
DPBS without calcium or magnesium (Gibco, Invitrogen) was
added to culture plates and maintained at least 4h at 37ºC.
Then, plates were washed at least three times with fresh DPBS.
NKs were cultured in antibody-coated plates with the differ-
ent treatments in NK MACS Medium (Miltenyi Biotec) sup-
plemented with 5% human male AB serum (Sigma-Aldrich)
and 500 IU/mL of IL-2 (Aldesleukin, Novartis) for 16h. Then,
cells were harvested and used for study by flow cytometry or
for subsequent experiments.
For NK long-term activation and expansion, NK cells were
cultured with allogeneic 20Gy irradiated PBMCs in a 10:1
ratio and 20Gy irradiated RPMI8866 lymphoblastoid cells in
a 4:1 ratio in RPMI 1640 medium with glutamax (Gibco,
Invitrogen). The culture medium was also supplemented
with 10% of heat-inactivated FBS, 10% human male AB
serum, 1mM non-essential aminoacids, 1mM sodium pyru-
vate, 2x10−5M beta-mercaptoethanol, 50U/mL of IL-2, 1µg/
mL PHA (Sigma-Aldrich), 100 IU/mL penicillin and 100 g/
mL streptomycin. Cultures were maintained during 7–14 days
and resulting activated NK cells were freshly used or cryopre-
served. NK purity was checked in every experiment and found
to be over 98%.
Cocultures of NKs and tumor cells
Activated NK cells were cocultured with MM1S-GFP-Luc or
KMS28-BM cells in a 1:1 ration in the presence or absence of
daratumumab and urelumab (10µg/mL). At 24h, part of the
Figure 4. Urelumab increases the antitumoral effect of daratumumab in immunodeficient mice inoculated with a MM1S-GFP-Luc multiple myeloma-derived cell line
and reconstituted with human NK cells (a and b) Tumor burden of mice monitored by bioluminescence. Censored pictures indicate mice which had died due to
myeloma progression. RLU represents relative light units from regions of interest. *** = p < 0.001 in a linear regression comparison test of Dara and [NK + Dara] vs.
[NK + Dara + Ure] groups. (c) Kaplan-Meier curves representing survival. *** = p < 0.001 in a Long-Rank test, comparing of [NK + Dara] vs. [NK + Dara + Ure] groups.
Graphs show data of one experiment from two performed with similar results.
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supernatants was collected and frozen for subsequent IFNɣ
concentration determination by commercial ELISA (R&D).
Part of the cells was used to study the tumor cell lysis percen-
tage by flow cytometry, and the rest of the culture was main-
tained with brefeldin A during 4h. Cytotoxicity was measured
as the percentage of non-viable (ZombieNir+ and/or active
caspase 3+) versus viable (ZombieNir− and active caspase 3−)
cells among GFP+ myeloma cells. At this point, cells were
harvested, and CD25, IFNɣ and other molecules expression
were studied by flow cytometry. Daratumumab was acquired
from Janssen. Elotuzumab and urelumab was obtained from
Bristol-Myers Squibb. Beriglobin P (CSL Behring) was used as
irrelevant human IgG.
Flow cytometry
Cells were pretreated with 10µg/mL of human IgG to reduce
nonspecific staining. Monoclonal antibodies to the human
antigens were conjugated to fluorescein isothiocyanate
(FITC), phycoerythrin (PE), PerCP-Cy5.5, allophycocyanin
(APC), AlexaFluor 488, Alexa Fluor 647, Brillant Violet 510,
Pacific Blue or Brillant Violet 421. Anti-CD137 (4B4-1), anti-
PD-L1 (29E.2AE), anti-Granzyme B (6B11), anti-LAG3
(3DS223H), anti-mCD11b (M1/70) and anti-CD45 (HI30)
were purchased from Biolegend. Anti-CD56 (NCAM16.2),
CD16 (3G8) and active Caspase 3 (C92-605) were obtained
from BD. Anti-CD3 (UCHT1), anti CD25 (BC96) and anti-
IFNɣ (4SB3) were from eBioscience and anti-NKG2A
(131411) was purchased from R&D System. To study the
expression of CD137 on NK cells previously treated with
urelumab, a biotilinated mAb developed by our group was
used (5D1). This mAb does not compete with urelumab in
binding to CD137.22 The anti-CD38 (Cy38F2) mAb was from
Cytognos. Intracellular staining (to study active Caspase 3 and
anti-IFNɣ expression) was performed with the BD Cytofix/
Cytoperm™ solution following the manufacturer’s protocol.
Dead cells were identified using the ZombieNIR™ kit
(Biolegend). FACSCanto II cytometer was used for cell acqui-
sition, and data analysis was performed using FACS DiVa
(BD Biosciences) and FlowJo 7.2.1 (Tree Star Inc., San
Carlos, CA).
In vivo model
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were pur-
chased from The Jackson Laboratory and bred in the animal
facility of CIMA of the University of Navarra under the
guidelines of Ethics Committee of the center following the
001–17 protocol. For the xenograft model, 3 × 106 MM1S-
GFP-Luc cells were inoculated i.v. via the caudal vein together
with 2 × 106 freshly isolated NK cells and 50µg of daratumu-
mab per mice. The following day, 100µg of urelumab were
injected i.v. In the activated NK cell model, 5 × 106 MM1S-
GFP-Luc cells were injected together with 4 × 106 activated
NK cells, 50µg of daratumumab and 100µg of urelumab per
mice at the same time.
Six weeks following tumor inoculation, bioluminescence
was measured once every week. For this purpose, mice were
anesthetized using ketamine/xylazine and injected with 100 μl
D-luciferine i.p. (Xenogen) at a concentration of 30 mg/ml.
Mice were placed in the imaging chamber of the
PhotonIMAGER Optima system (Biospace labs). A color-
scale photograph of the animals was acquired, followed by
bioluminescent acquisition. Regions of interest were drawn
over the animal image, as well as over regions of no signal,
which were used as background readings. Light intensity was
quantified using photons/s (RLU). The color-scale photo-
graph and data images from all studies were superimposed
using M3 Vision software (Biospace labs).
Statistical analysis
Prism software (GraphPad Software) was used for statistical
analysis. For in vitro experiments, differences between groups
were verified with t-student, paired T tests or one-way
ANOVA tests. Linear regression was used to compare photon
emission in bioluminescence experiments. In vivo luciferase
expression was analyzed by differences in linear regression
after logarithmic transformation of the data. Mice survival
was studied with Log-Rank (Mantel-Cox) test. *p < 0.05,
**p < 0.01, ***p < 0.001.
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